Breckenridge Pharmaceutical Expands Oncology Offerings with New Pomalidomide Capsules
Breckenridge Pharmaceutical, Inc., the American branch of Towa International, has progressed significantly in its fight against cancer by introducing Pomalidomide Capsules to the market. This latest product is a generic form of Pomalyst®, previously developed by Celgene and currently under Bristol Myers Squibb's management. The launch, executed in partnership with India's NATCO Pharma Limited, marks a vital step forward in Breckenridge's extensive oncology portfolio.
The introduction of Pomalidomide Capsules is primarily aimed at aiding adult patients suffering from multiple myeloma who have undergone at least two previous therapies, including treatments with lenalidomide and a proteasome inhibitor. Unfortunately, many of these patients experience disease progression shortly after completing their last therapy, complicating their treatment journey. Additionally, this medication is also effective for individuals dealing with AIDS-related Kaposi sarcoma who have not responded to highly active antiretroviral therapy, as well as for HIV-negative adults suffering from the same condition.
Available in several strengths of 1 mg, 2 mg, 3 mg, and 4 mg, Pomalidomide Capsules will be distributed primarily through specialty pharmacies and medical clinics. This launch is particularly significant given the ongoing challenge that patients face in accessing affordable specialty therapies. According to Brian Guy, President and Chief Commercial Officer of Breckenridge Pharmaceutical, this new offering not only delivers a high-quality product but also includes co-pay assistance, which can help alleviate some of the financial burden on patients.
"Access and affordability remain significant hurdles for patients relying on specialty therapeutics," Guy emphasized. "The introduction of Pomalidomide Capsules is a testament to our commitment to providing high-quality, affordable options that enhance continuity of care. Our focus continues to be on expanding our specialty generics range and improving the accessibility of these critical therapies for patients facing challenging health conditions."
Equally optimistic, Rajeev Nannapaneni, Vice Chairman and CEO of NATCO Pharma Limited, noted, "We are thrilled to present Pomalidomide Capsules in the United States, which underscores our dedication to improving patient access to specialty medicines. We are committed to advancing our oncology offerings and are excited about the potential to introduce additional complex medications to the market in the near future."
It’s important to note that Pomalidomide Capsules are administered through a restricted program known as PS-Pomalidomide REMS. Detailed prescribing information, including boxed warnings, is available for healthcare professionals, ensuring they are well-informed about the administration and potential risks associated with this treatment.
In summary, Breckenridge Pharmaceutical's launch of Pomalidomide Capsules represents a critical advancement in oncology therapy, reaffirming the company's mission to deliver effective, affordable treatment options to those who need them most. With collaborations like NATCO Pharma, they are not only expanding their portfolio but are also contributing positively to the wider healthcare landscape where specialty medications are crucial for patient survival and quality of life.
The introduction of Pomalidomide Capsules is primarily aimed at aiding adult patients suffering from multiple myeloma who have undergone at least two previous therapies, including treatments with lenalidomide and a proteasome inhibitor. Unfortunately, many of these patients experience disease progression shortly after completing their last therapy, complicating their treatment journey. Additionally, this medication is also effective for individuals dealing with AIDS-related Kaposi sarcoma who have not responded to highly active antiretroviral therapy, as well as for HIV-negative adults suffering from the same condition.
Available in several strengths of 1 mg, 2 mg, 3 mg, and 4 mg, Pomalidomide Capsules will be distributed primarily through specialty pharmacies and medical clinics. This launch is particularly significant given the ongoing challenge that patients face in accessing affordable specialty therapies. According to Brian Guy, President and Chief Commercial Officer of Breckenridge Pharmaceutical, this new offering not only delivers a high-quality product but also includes co-pay assistance, which can help alleviate some of the financial burden on patients.
"Access and affordability remain significant hurdles for patients relying on specialty therapeutics," Guy emphasized. "The introduction of Pomalidomide Capsules is a testament to our commitment to providing high-quality, affordable options that enhance continuity of care. Our focus continues to be on expanding our specialty generics range and improving the accessibility of these critical therapies for patients facing challenging health conditions."
Equally optimistic, Rajeev Nannapaneni, Vice Chairman and CEO of NATCO Pharma Limited, noted, "We are thrilled to present Pomalidomide Capsules in the United States, which underscores our dedication to improving patient access to specialty medicines. We are committed to advancing our oncology offerings and are excited about the potential to introduce additional complex medications to the market in the near future."
It’s important to note that Pomalidomide Capsules are administered through a restricted program known as PS-Pomalidomide REMS. Detailed prescribing information, including boxed warnings, is available for healthcare professionals, ensuring they are well-informed about the administration and potential risks associated with this treatment.
In summary, Breckenridge Pharmaceutical's launch of Pomalidomide Capsules represents a critical advancement in oncology therapy, reaffirming the company's mission to deliver effective, affordable treatment options to those who need them most. With collaborations like NATCO Pharma, they are not only expanding their portfolio but are also contributing positively to the wider healthcare landscape where specialty medications are crucial for patient survival and quality of life.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.